Latest Regulatory Approvals News

Tanami Gold NL has released final assay results from its 2025 drilling campaigns at the Jims Gold Mine and Defa Prospect, confirming extensive gold mineralisation and promising high-grade zones that could underpin future mining development.

1414 Degrees secures critical approvals from AEMO and ElectraNet for its 140 MW Aurora Battery Energy Storage System, advancing the project toward grid connection and commercial operation in 2026.

Ausgold Limited has delivered an updated Definitive Feasibility Study for its Katanning Gold Project, revealing increased gold production and enhanced financial returns, supported by a $90 million capital raise to accelerate development.

Proteomics International has been granted a Canadian patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma. This milestone strengthens its global intellectual property portfolio and paves the way for commercial expansion in North America.

Osteopore Limited has secured an exclusive multi-year distribution agreement with Majeton to commercialise its dental and maxillofacial products in China, Hong Kong, and Macau, marking a major step in its Asia-Pacific expansion.

Evolution Energy Minerals has resumed soil sampling at its Chikundo Copper Project in Tanzania, moving closer to a planned drilling campaign in 2026. The latest phase aims to refine drill targets and accelerate exploration progress.

Lunnon Metals has completed a detailed Feasibility Study for its Lady Herial gold deposit, outlining a robust, short-life open pit mine with strong pre-tax cash flows exceeding $40 million. The project is fully permitted and poised for imminent development.

Lunnon Metals and St Ives Gold Mining have finalized the mine schedule for Lady Herial, making their Ore Purchase Agreement unconditional and setting the stage for mining to begin.

Findi Limited has landed a significant pre-IPO investment from Nova Global Opportunities Fund PCC, setting the stage for its Indian subsidiary’s planned listing on the Bombay Stock Exchange by FY27. This deal supports a Findi share price target between $5.58 and $6.69.

ReNerve Limited has secured market approval for its NervAlign® Nerve Cuff in Malaysia, marking a key milestone in its Asia-Pacific expansion strategy. This approval follows earlier clearances in Hong Kong and Thailand, positioning the company to tap into a growing regional nerve repair market.

Southern Cross Gold Consolidated Ltd. has achieved a pivotal regulatory milestone enabling underground exploration at its Sunday Creek project, backed by strong drilling results and a robust cash position of $130.4 million.

Neuren Pharmaceuticals’ partner Acadia projects DAYBUE sales to reach around US$700 million by 2028, driven by US market expansion and international approvals. The launch of a new formulation and ongoing clinical trials in Japan underpin this optimistic outlook.